Teaching corner': Management of diabetic retinopathy

Malawi Medical Journal

Volumn 25, Issue 4, 2013, Pages 116-120

  Ellis, D ^a   Burgess, P I ^b   Kayange, P ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b QUEEN ELIZABETH CENTRAL HOSPITAL   (Malawi)

^c UNIVERSITY OF MALAWI   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIABETIC RETINOPATHY; DISEASE MANAGEMENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE MANAGEMENT; HUMANS; RISK FACTORS;

EID: 84897823453     PISSN: 19957262     EISSN: 19957270     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. IDF (2009). Diabetes atlas (4th edn). International Diabetes Federation, Brussels.
2. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. BJO 2012; 96(5):614-618.
3. Malawi National STEPS Survey for Chronic Non-Communicable Diseases and their Risk Factors. World Health Organisation, 2010. http://www.who.int/chp/steps/Malawi_2009_STEPS_Report.pdf (accessed 4th August 2013)
4. Younis N, Broadbent D, Vora J and Harding S. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361: 195-200.
5. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
6. Klein R et al. The Wisconsin Epidemiological Study of Diabetic Retinopathy: II. Prevalence and Risk of Diabetic Retinopathy when Age at Diagnosis is Less than 30 Years. Archives of Ophthalmology 1984; 102 (4): 520-526.
7. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329: 977-986
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
9. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR: UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001, 44:156-163.
10. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
11. The ACCORD Study Group and ACCORD Eye Study Group. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med 2010;363:233-44.
12. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
13. Harding SP, Broadbent DM, Neoh C et al. Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool diabeticeye study. BMJ 1995; 311: 1131-5.
14. Diabetes control and complications trial. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995 Aug;44(8):968-83.
15. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126 (12): 1707-1715.
16. Royal college of Ophthalmologists. Diabetic retinopathy guidelines 2012 http://www.rcophth.ac.uk/page.asp?section=451§ionTitle=C linical+Guidelines (Accessed 4th August 2013)
17. Chew EY, Klein ML, Ferris FL III, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84.
18. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21-27;364(9435):685-696.
19. American Diabetes Association. Management of Dyslipidemia in Adults in Diabetes. Diabetes Care 2007; 25 (1): S74-S77.
20. Merante D, Menchini F, Truitt KE, Bandello FM. Diabetic macular edema: correlations with available diabetes therapies--evidence across a qualitative review of published literature from MEDLINE and EMBASE. Drug Saf. 2010 Aug 1;33(8):643-52.
21. Davis MD et al. Effect of Ruboxistaurin on the Visual Acuity Decline Associated with Long-standing Diabetic Macular Edema. Investigative Ophthalmology and Visual Science 2009; 50 (1): 1-4.
22. Aiello LP et al. Oral Protein Kinase C β Inhibition using Ruboxistaurin: Efficacy, Safety and Causes of Vision Loss Among 813 Patients (1392 eyes) with Diabetic Retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina 2011; 31 (10): 2084-2094.
23. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010; 33(8):1872-1894.
24. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabetic Medicine. 2010; 27: 249-256.
25. Mash B, Powell D, du Plessis F, van Vuuren U, Michalowska M, Levitt N. Screening for diabetic retinopathy in primary care with a mobile fundal camera--evaluation of a South African pilot project. S Afr Med J. 2007 Dec;97(12):1284-8.
26. Mumba M, Hall A, Lewallen S. Compliance with eye screening examinations among diabetic patients at a Tanzanian referral hospital. Ophthalmic Epidemiol. 2007 Sep-Oct;14(5):306-10.
27. NHS Dibetic eye screening programme. http://diabeticeye. screening.nhs.uk Accessed 8th February 2013
28. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8.Ophthalmology 1981; 88: 583-600.
29. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthal 1985; 103: 1796-1806
30. DRCR Network. Beck RW, Edwards AR, Aiello LP et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127(3):245-251.
31. DRCR Network. Elman MJ, Aiello LP, Beck RW et al. Randomized Trial Evaluating Ranibizumab Plus Promptor Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology; 117(6): 1064-1077.
32. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz- Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K; FAME Study Group Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema. Ophthalmology. 2012 Jun 21. [Epub ahead of print]
33. Boulton M. VEGF localisation in diabetic retinopathy. British Journal of Ophthalmology 1998; 82: 561-568.
34. DRCR network. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2010; 117:1064-1077.
35. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD et al. A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema: 24-Month Data: Report 3. Arch.Ophthalmol. 2012; 130: 972-979
36. Tao Y, Jiang YR, Li XX, Gao L, Jonas JB. Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment. Retina. 2010 Mar;30(3):447-51.
37. Glover SJ et al. Prevalence of diabetic retinopathy, cataract and visual impairment in patients with diabetes in sub-Saharan Africa. British Journal of Ophthalmology 2012; 96 (2): 156-161.
38. Bradshaw D, et al: Estimating the burden of disease attributable to diabetes in South Africa in 2000. S Afr Med J 2007, 97(8 Pt 2):700-6.
39. Report on the United Nations high level meeting on non-communicable disease prevention and control. http://www.who.int/ nmh/events/un_ncd_summit2011/en/. Accessed 4th February 2013
40. Burgess PI, Msukwa G, Beare NAV. Diabetic retinopathy in Sub- Saharan Africa: meeting the challenges of an emerging epidemic. BMC Medicine. 2013 Jul 2;11:157